NetworkNewsBreaks – Odyssey Health Inc. (ODYY) R
Post# of 85
(Total Views: 162)
Posted On: 11/23/2022 4:30:08 PM
NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update
Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps to develop the drug, including appointing two new members of the management team with expertise in progressing drugs through the clinical phase and to the market; completing an FDA-required IND in order to move forward with a phase 1 human trial; developing a nanoparticle spray-dried formulation for intranasal delivery to enhance brain uptake; and developing and manufacturing a novel breath-propelled intranasal delivery device along with filing a patent application for that device. Odyssey has also contracted with two world-class research organizations, Avance Clinical Pty Ltd. and Nucleus Networks, to conduct a phase I clinical trial, and completed the phase 1 human clinical trial to show the drug is safe and well tolerated. In addition, the company has raised more than $5 million to support its development efforts.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps to develop the drug, including appointing two new members of the management team with expertise in progressing drugs through the clinical phase and to the market; completing an FDA-required IND in order to move forward with a phase 1 human trial; developing a nanoparticle spray-dried formulation for intranasal delivery to enhance brain uptake; and developing and manufacturing a novel breath-propelled intranasal delivery device along with filing a patent application for that device. Odyssey has also contracted with two world-class research organizations, Avance Clinical Pty Ltd. and Nucleus Networks, to conduct a phase I clinical trial, and completed the phase 1 human clinical trial to show the drug is safe and well tolerated. In addition, the company has raised more than $5 million to support its development efforts.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Odyssey Group Intl Inc (ODYY) Stock Research Links
Scroll down for more posts ▼